ANCA in dialysis patients: A role for bioincompatibility?

International Journal of Artificial Organs

Volumn 23, Issue 2, 2000, Pages 97-103

  Andreini, B ^a   Panichi, Vincenzo ^a,g   Cirami, C ^a   Migliori, M ^a   De Pietro, S ^a   Taccola, D ^a   Aloisi, M ^b   Antonelli, A ^c   Giusti, R ^c   Rindi, P ^d   Buoncristiani, U ^e   Giovannini, L ^a   Palla, R ^f  

^a UNIVERSITY OF PISA   (Italy)

^b Nephrology Unit of Pietrasanta   (Italy)

^c Nephrology and Dialysis Unit   (Italy)

^d Nephrology Unit of Pisa   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f Nephrology Unit of Massa   (Italy)

^g SANTA CHIARA HOSPITAL   (Italy)

Author keywords

ANCA; Biocompatibility; Hemodialysis MPO; PR 3

Indexed keywords

BIOCOMPATIBILITY; DIALYSIS MEMBRANES; HEMODIALYZERS; PATIENT TREATMENT;

ANTI-NEUTROPHILE CYTOPLASMIC AUTOANTIBODY; AUTOANTIBODIES; HAEMODIALYSIS; HEMODIALYSIS MPO; PATHOLOGICAL CONDITIONS; PATIENT'S SUFFERING; PERITONEAL DIALYSIS; PR-3; VASCULITIS; WEGENER GRANULOMATOSIS;

DIALYSIS;

AUTOANTIBODY; BICARBONATE; CALCIUM ANTAGONIST; CELL NUCLEUS ANTIGEN; CLONIDINE; CUPROPHANE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; LACTIC ACID; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; POLY(METHYL METHACRYLATE); POLYACRYLONITRILE; POLYAMIDE; POLYCARBONATE; POLYSULFONE; PROTEINASE ACTIVATED RECEPTOR 3;

ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; BLOOD LEVEL; CLINICAL TRIAL; CONTAMINATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DIALYSIS MEMBRANE; FEMALE; HEMOFILTRATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; UREMIA; VASCULITIS;

EID: 0034108585     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880002300206     Document Type: Article

References (33)

1. Direskenely H, Ozgun S, Ozener C, et al. Anti-lymphocyte, anti-endothelial cell antibodies in chronic hemodialysis patients. Nephrol Dial Transplant 1992; 7: 422-6.
2. Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J 1982; 285: 606.
3. van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-9.
4. Andrassy K, Koderish J, Rufer M, Erb A, Waldher R, Ritz E. Detection and clinical implication of antineutrophil cytoplasm in Wegener's granulomatosis and rapidly progressive glomerulonephritis. Clin Nephrol 1989; 32: 159-67.
5. Merkel PA, Polisson RP, Chang Y et al. Prevalence of antineutrophil cytoplasmatic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997; 126: 866-71.
6. Rasmussen PB, Bjorn S, Hastrup S, et al. Characterization of recombinant human HBP/CAP37/azurocidin, a pleiotropic mediator of inflammation-enhancing LPS-induced cytokine release from monocytes. FEBS Lett. 1996; 15: 109-112.
7. Zaho MH, Lockwood CM. Azurocidin is a novel antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in systemic vasculitis. Clin Exp Immunol 1996; 103: 397-402.
8. Wiik A, van der Woude FJ. The new ACPA/ANCA nomenclature. Neth J Med 1990; 36, 107.
9. Hagen EC, Daha MR, Hermans J, et al. for the EC/BCR project for ANCA assay standardization. Diagnostic value of standardized assays for anti-neutrophil cytoplasmatic antibodies in idiopathic systemic vasculitis. Kidney Int 1998; 53: 745-53.
10. Craddock, PR, Fehr J, Dalmasso AP, Brigham KL, Jacob HS. Hemodialysis leukopenia: pulmonary vascular leukostasis resulting from completed activation by dialyzer cellophane membranes. J Clin Invest 1977; 59: 879-88.
11. Horl WH, Jochum M, Heidland A, Fritz H. Release of granulocyte proteinases during hemodialysis. Am J Nephrol 1983; 3: 213-17.
12. Heidland A, Horl WH, Heller N, Heine H, Neuman S, Heidbrer E. Proteolytic enzymes and catabolism - enhanced release of granulocyte proteinases in uremic intoxication and during hemodialysis. Kidney Int 1983; 24: S27-S36.
13. Wiik A. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. Acta Pathol Microbiol Immunol Scand 1989; 97: S12-S18.
14. Roberts DE, Peebles C, Dagget R. A simplified method of preparing neutrophillides in the examination for antibodies to cytoplasmic antigens. J Clin Pathol 1990; 43: 83-4.
15. Rosenboom S, Rautmann A, Gross WL. Detection of anti-cytoplasmic antibodies by the indirect immunofluorescence technique: Methodological aspects and staining pattern. Acta Pathol Microbiol Immunol Scand 1989; 97: S32-S36.
16. Weidemann S, Andrassy K, Ritz E. ANCA in hemodialysis patients. Nephrol Dial Transplant 1993; 8: 839-45.
17. Ewert BH, Jennette JC, Falk RJ. The pathogenetic role of antineutrophil cytoplasmic autoantibodies. Am J Kidney Dis 1991; 18: 188-95.
18. Lesavre P. Antineutrophil Cytoplasmic Autoantibodies antigen specificity. Am J Kidney Dis 1991; 18: 159-63.
19. Lockwood CM. Specificity and pathogenicity of Antineutrophil Cytoplasm Antibodies. Exp Nephrol 1993; 1: 13-8.
20. Ewert BH, Jennette JC, Falk RJ. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992; 41: 375-83.
21. Bagdade JD. Chronic renal failure and atherogenesis: serum factors stimulate the proliferation of human arterial smooth muscle cells. Atherosclerosis 1979; 34: 243-6.
22. Newman W, Beall LD, Levine MA, Cone JL, Raudhawa ZI, Bartolini DR. Biotinylated parathyroid hormone as a probe for the parathyroid hormone receptor. Structure function analysis and detection of specific binding to cultured bone cells by flow cytometry. J Biol Chem 1989; 264: 359-65.
23. Pun KK, Ho PW. Identification and characterization of parathyroid hormone receptors on dog kidney, human kidney, chick bone and dermal fibrolast. A comparative study of functional and structural properties. Biochem J 1989; 259: 785-9.
24. Horl WH, Schaefer RM, Heidland A. Effect of different dialyzers on proteinases and proteinase inhibitors during hemodialysis. Am J Nephrol 1985; 5: 320-6.
25. Horl WH, Riegel W, Schollmeyer P, Rautemberg W, Neumann S. Different complement and granulocyte activation in patients dialyzed with PMMA dialyzers. Clin Nephrol 1986; 25: 304-7.
26. Johnson RJ. The mystery of the antineutrophil cytoplasmic antibodies. Am J Kidney Dis 1995; 26: 57-61.
27. Bender JG, Mc Phaid LC, van EPPS DC. Exposure of human neutrophil to chemotactic factors potentiates activation of the respiratory burst. J Immunol 1983; 30: 2316-19.
28. Atkinson YH, Marasco WA, Lopez AF, Vadas MA. Recombinant human tumor necrosis factor-alpha. Regulation of N-Formilmethionylleucyphenylalanine receptor affinity and function on human neutrophils. J Clin Invest 1988; 81: 759-63.
29. Charles LA, Caldas ML, Falk RJ, Terrel RS, Jennet JC. Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol 1991; 50: 539-46.
30. Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994; 95: 244-50.
31. Bommer J, Becker KP, Urbascheck. Potential transfer of endotoxins across high-flux polysulfone membranes. JASN 1988; 7: 883-88.
32. Lonneman G, Behme TC, Lenzner B. Permeability of dialyser membranes to TNFα-inducing substances derived from water bacteria. Kidney Int 1992; 42: 61-8.
33. Panichi V, De Pietro S, Andreini B. et al. Cytokine production in hemodiafiltration: a multicentre study. Nephrol Dial Transplant 1998; 13: 1737-44.